DLHCMEDIUM SIGNALFINANCIAL10-K

DLHC experienced a significant 44% decline in net income despite 17% gross profit growth, indicating deteriorating operational efficiency and rising expenses.

The disconnect between improving gross margins and falling net income suggests the company is struggling with cost management, possibly due to increased overhead or interest expenses from their substantial debt load. The 64% cash decline to just $125K creates potential liquidity concerns despite debt reduction efforts.

Comparing 2025-12-10 vs 2024-12-04View on EDGAR →
FINANCIAL ANALYSIS

DLHC shows mixed financial performance with gross profit increasing 17% to $30.2M while net income fell 44% to $1.8M, indicating significant expense inflation that overwhelmed revenue improvements. The balance sheet strengthened through debt reduction from $149.4M to $128.0M and proportional decreases in receivables and liabilities, but the dramatic 64% cash decline to just $125K raises immediate liquidity concerns. Overall, the company appears to be managing debt but struggling with operational efficiency and working capital management.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-63.5%
$342K→$125K

Cash declined 63.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-44.2%
$3.3M→$1.8M

Net income declined 44.2% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-32.6%
$24.9M→$16.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Accounts Receivable
Balance Sheet
-23%
$49.8M→$38.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Liabilities
Balance Sheet
-19.9%
$53.2M→$42.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-19.7%
$53.0M→$42.5M

Current assets declined 19.7% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
+16.8%
$25.9M→$30.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Cash Flow
Cash Flow
-15.2%
$27.4M→$23.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Debt
Balance Sheet
-14.3%
$149.4M→$128.0M

Debt reduced 14.3% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
-13%
$204.2M→$177.7M

Liabilities reduced 13% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2025-12-10
PRIOR — 2024-12-04
ADDED
As of December 9, 2025 there were 14,493,035 shares of the Registrant s common stock outstanding.
Our revenue is distributed to time and materials contracts (51.4%), firm fixed price contracts (27.2%) and cost reimbursable contracts (21.4%).
Our customers, including numerous institutes and centers within the National Institutes of Health ("NIH"), the Defense Health Agency ("DHA"), US Army Medical Research Development Command ("MRDC"), and US Navy, rely on our information technology support to enable their vital missions.
We primarily provide large-scale data analytics, testing and evaluation, clinical trials research services, and epidemiology studies to support multiple operating divisions within HHS, including NIH and the Center for Disease Control and Prevention ("CDC"), as well as the Military Health System.
This includes specialized engineering expertise, encompassing areas of Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, and Reconnaissance ("C5ISR"), modeling, simulation training, performance based logistics, system modernization, technology-powered health solutions and software engineering on behalf of the US Navy, HHS, VA, and other federal customers.
+7 more — sign up free →
REMOVED
As of December 2, 2024 there were 14,386,468 shares of the Registrant s common stock outstanding.
Our revenue is distributed to time and materials contracts (54%), firm fixed price contracts (26%) and cost reimbursable contracts (20%).
Our customers, including numerous institutes and centers within the National Institutes of Health ("NIH"), the Defense Health Agency ("DHA"), Telemedicine and Advanced Technology Research Center ("TATRC"), and US Navy Naval Information Warfare Center ("NIWC"), rely on our information technology support to enable their vital missions.
We work with these customers to reduce risk and build resilience to cyber and physical threats to the federal government s infrastructure, providing the full spectrum of cyber capabilities, cryptographic and true cyber engineering, Certified Information Security Officer ("CISO") / Information System Security Officer ("ISSO") support, risk management frameworks, Continuity of Operations ("COOP") / Disaster Recovery, and enterprise infrastructure and cloud governance focused on designing and implementing zero trust architecture.
We primarily provide large-scale data analytics, testing and evaluation, clinical trials research services, and epidemiology studies to support multiple operating divisions within HHS, including NIH and the Center for Disease Control and Prevention ("CDC"), the Military Health System, and leading academic institutes.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →